Akihiro Ohmoto

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 22

Top Topics

Acute Myeloid Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Practice

Helicobacter Pylori

Top Venues

Expert review of anti-infective therapy

Expert review of hematology

Expert review of anticancer therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Akihiro Ohmoto, Shigeo Fuji
Non-cancerous complications in HTLV-1 carriers. Expert review of anti-infective therapy (2024)
Akihiro Ohmoto, Shigeo Fuji
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. Expert review of anti-infective therapy 22 (4) (2024)
Akihiro Ohmoto, Shigeo Fuji
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. Expert review of anti-infective therapy (2024)
Akihiro Ohmoto, Shigeo Fuji
Non-cancerous complications in HTLV-1 carriers. Expert review of anti-infective therapy 22 (5) (2024)
Akihiro Ohmoto, Shigeo Fuji
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. Expert review of anti-infective therapy 22 (4) (2024)
Akihiro Ohmoto, Shigeo Fuji
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. Expert review of anti-infective therapy (2024)
Akihiro Ohmoto, Shigeo Fuji
Non-cancerous complications in HTLV-1 carriers. Expert review of anti-infective therapy 22 (5) (2024)
Akihiro Ohmoto, Shigeo Fuji
Non-cancerous complications in HTLV-1 carriers. Expert review of anti-infective therapy 22 (5) (2024)
Akihiro Ohmoto, Shigeo Fuji
Non-cancerous complications in HTLV-1 carriers. Expert review of anti-infective therapy (2024)
Akihiro Ohmoto, Shigeo Fuji
Letermovir for cytomegalovirus infection in allogeneic hematopoietic stem-cell transplantation: tips and notes for effective use in clinical practice. Expert review of anti-infective therapy 22 (4) (2024)
Akihiro Ohmoto, Shigeo Fuji
Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors. Expert review of hematology (2023)
Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, Hirotaka Suto, Shohei Udagawa, Ryosuke Oki, Yasuyoshi Sato, Mayu Yunokawa, Makiko Ono, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Shunji Takahashi
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PloS one 18 (3) (2023)
Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, Hirotaka Suto, Shohei Udagawa, Ryosuke Oki, Yasuyoshi Sato, Mayu Yunokawa, Makiko Ono, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Shunji Takahashi
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PloS one 18 (3) (2023)
Akihiro Ohmoto, Kenji Nakano, Naoki Fukuda, Xiaofei Wang, Tetsuya Urasaki, Naomi Hayashi, Hirotaka Suto, Shohei Udagawa, Ryosuke Oki, Yasuyoshi Sato, Mayu Yunokawa, Makiko Ono, Masanori Saito, Yusuke Minami, Keiko Hayakawa, Taisuke Tanizawa, Keisuke Ae, Seiichi Matsumoto, Junichi Tomomatsu, Shunji Takahashi
Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study. PloS one 18 (3) (2023)
Akihiro Ohmoto, Shigeo Fuji
Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors. Expert review of hematology (2023)
Akihiro Ohmoto, Shigeo Fuji
Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen. Expert review of hematology (2023)
Akihiro Ohmoto, Yu Fujiwara, Nobuyuki Horita, Kenji Nakano, Shunji Takahashi
Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discover. Oncology 13 (1) (2022)
Akihiro Ohmoto, Shigeo Fuji, Satoshi Kohmo, Kaoruko Katsura
HTLV-I associated bronchioloalveolar disorder (HABA): disease concept and differential diagnosis of an unsolved disease entity. Expert review of anti-infective therapy (2022)
Shigeo Fuji, Akihiro Ohmoto
Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. Expert review of hematology 15 (1) (2022)
Akihiro Ohmoto, Shigeo Fuji
Clinical feasibility of oral low-dose etoposide and sobuzoxane for conventional chemotherapy-intolerant lymphoma patients. Expert review of anticancer therapy 21 (7) (2021)
Akihiro Ohmoto, Shigeo Fuji
Current status of drug repositioning in hematology. Expert review of hematology (2021)
Akihiro Ohmoto, Shinichi Yachida, Chigusa Morizane
Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer. International journal of molecular sciences 20 (3) (2019)